Dr. Wassim Abida.

Dr. Abida is Director of Translational Research in Prostate Cancer, Associate Member in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and Associate Professor of Medicine at Weill Cornell Medical College. His research focuses on the genomics of prostate cancer and on the development of molecularly-guided therapies in prostate cancer and other solid tumors.

He leads analysis of MSKCC’s prostate cancer clinical-genomic dataset and is involved in multiple international prostate cancer genomics efforts. He also leads clinical trials investigating DNA repair and epigenetic-targeting agents in prostate cancer and other malignancies. One of these trials resulted in the first FDA approval of a PARP inhibitor, rucaparib, for the treatment of prostate cancer.

Dr. Abida obtained his M.D. and Ph.D. degrees at Columbia University and completed internal medicine residency training at the Hospital of the University of Pennsylvania. He completed his medical oncology fellowship training at Memorial Sloan Kettering Cancer Center, where he studied mechanisms of androgen receptor activity in the laboratory of Dr. Charles L. Sawyers, and served as Chief Fellow in hematology/oncology. He has received funding from the NCI, Department of Defense CDMRP and the Prostate Cancer Foundation.